(VIANEWS) – MercadoLibre (MELI), Primoris Services Corporation (PRIM), Global Self Storage (SELF) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. MercadoLibre (MELI)
37.1% sales growth and 45.15% return on equity
MercadoLibre, Inc. operates online commerce platforms in Latin America. It operates Mercado Libre Marketplace, an automated online commerce platform that enables businesses, merchants, and individuals to list merchandise and conduct sales and purchases online; and Mercado Pago FinTech platform, a financial technology solution platform, which facilitates transactions on and off its marketplaces by providing a mechanism that allows its users to send and receive payments online, as well as allows users to transfer money through their websites or on the apps. The company also offers Mercado Fondo that allows users to invest funds deposited in their Mercado Pago accounts; Mercado Credito, which extends loans to certain merchants and consumers; and Mercado Envios logistics solution that enables sellers on its platform to utilize third-party carriers and other logistics service providers, as well as fulfillment and warehousing services for sellers. In addition, it provides Mercado Libre Classifieds, an online classified listing service, where users can list and purchase motor vehicles, real estate, and services; Mercado Libre Ads, an advertising platform, which enables large retailers and brands to promote their products and services on the web; and Mercado Shops, an online storefronts solution that enables users to set-up, manage, and promote their own digital stores. The company was incorporated in 1999 and is headquartered in Montevideo, Uruguay.
Earnings Per Share
As for profitability, MercadoLibre has a trailing twelve months EPS of $19.65.
PE Ratio
MercadoLibre has a trailing twelve months price to earnings ratio of 81.16. Meaning, the purchaser of the share is investing $81.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 45.15%.
Moving Average
MercadoLibre’s value is way higher than its 50-day moving average of $1,331.79 and way above its 200-day moving average of $1,270.69.
Volume
Today’s last reported volume for MercadoLibre is 122920 which is 68.35% below its average volume of 388385.
Revenue Growth
Year-on-year quarterly revenue growth grew by 39.8%, now sitting on 13.21B for the twelve trailing months.
Sales Growth
MercadoLibre’s sales growth is 36.5% for the current quarter and 37.1% for the next.
2. Primoris Services Corporation (PRIM)
29.5% sales growth and 11.48% return on equity
Primoris Services Corporation, a specialty contractor company, provides a range of construction, fabrication, maintenance, replacement, and engineering services in the United States and Canada. It operates through three segments: Utilities, Energy/Renewables, and Pipeline Services. The Utilities segment offers installation and maintenance services for new and existing natural gas distribution systems, electric utility distribution and transmission systems, and communications systems. The Energy/Renewables segment provides a range of services, including engineering, procurement, and construction, as well as retrofits, highway and bridge construction, demolition, site work, soil stabilization, mass excavation, flood control, upgrades, repairs, outages, and maintenance services to renewable energy and energy storage, renewable fuels, petroleum, refining, and petrochemical industries, as well as state departments of transportation. The Pipeline Services segment offers a range of services comprising pipeline construction, maintenance, facility, and integrity services; installation of compressor and pump stations; and metering facilities for entities in the petroleum and petrochemical industries, as well as gas, water, and sewer utilities. The company was founded in 1960 and is headquartered in Dallas, Texas.
Earnings Per Share
As for profitability, Primoris Services Corporation has a trailing twelve months EPS of $2.4.
PE Ratio
Primoris Services Corporation has a trailing twelve months price to earnings ratio of 13.39. Meaning, the purchaser of the share is investing $13.39 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.48%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Dec 27, 2023, the estimated forward annual dividend rate is 0.24 and the estimated forward annual dividend yield is 0.75%.
Yearly Top and Bottom Value
Primoris Services Corporation’s stock is valued at $32.13 at 14:22 EST, way under its 52-week high of $36.19 and way above its 52-week low of $20.44.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.1%, now sitting on 5.53B for the twelve trailing months.
Moving Average
Primoris Services Corporation’s worth is higher than its 50-day moving average of $30.69 and higher than its 200-day moving average of $29.42.
3. Global Self Storage (SELF)
10.7% sales growth and 4.73% return on equity
Global Self Storage is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible and secure storage space for residential and commercial customers. Through its wholly owned subsidiaries, the company owns and/or manages 13 self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
Earnings Per Share
As for profitability, Global Self Storage has a trailing twelve months EPS of $0.2.
PE Ratio
Global Self Storage has a trailing twelve months price to earnings ratio of 23.2. Meaning, the purchaser of the share is investing $23.2 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.73%.
4. Regeneron Pharmaceuticals (REGN)
8.6% sales growth and 17.22% return on equity
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Earnings Per Share
As for profitability, Regeneron Pharmaceuticals has a trailing twelve months EPS of $35.02.
PE Ratio
Regeneron Pharmaceuticals has a trailing twelve months price to earnings ratio of 24.01. Meaning, the purchaser of the share is investing $24.01 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.22%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Regeneron Pharmaceuticals’s EBITDA is 6.23.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.5%, now sitting on 13.1B for the twelve trailing months.
